Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar;6(1):29-39.
doi: 10.1007/s11523-011-0179-4. Epub 2011 Apr 28.

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

Sushma Vemulapalli  1 , Alain Mita, Yesid Alvarado, Kamalesh Sankhala, Monica Mita
Affiliations
Review

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

Sushma Vemulapalli et al. Target Oncol. 2011 Mar.

Abstract

The mammalian target of rapamycin (mTOR) is a protein kinase that functions as a key regulator of cell growth, proliferation and differentiation, cell-cycle progression, angiogenesis, protein degradation, and apoptosis. Following activation by a number of oncogenic signals such as growth factors, energy and nutrients, mTOR stimulates several downstream effectors including the 40S ribosomal protein S6 kinase (p70s6k) and the eukaryotic initiation factor 4 E binding protein-1 (4 EBP-1), as well as a complex network of regulatory loops. Activation of the mTOR pathway plays a critical role in the development of many tumor types, including renal cell and breast carcinomas, neuroendocrine tumors, and sarcomas. Bone and soft tissue sarcomas are rare, heterogeneous tumors that are curable by local treatments if diagnosed at early stages; however advanced or metastatic sarcomas are rarely curable and very few drugs are efficacious in this setting. Several disruptions in phosphatidylinositol-3 kinase (PI3K)-Akt-mTOR signaling are associated with malignant transformation or progression in various sarcoma sub-types. The PI3K-Akt-mTOR pathway is therefore an exciting target for therapy of sarcomas, and its blockade represents an opportunity to improve outcomes in this poor-prognosis disease. Early studies with mTOR inhibitors have demonstrated promising antitumor activity in patients with metastatic sarcoma who have failed standard treatments. This article discusses the mTOR signaling pathway and summarizes the clinical experience with mTOR inhibitors in patients with advanced or metastatic sarcoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Oncol. 2004 Jul 15;22(14):2954-63 - PubMed
    1. J Cancer Res Clin Oncol. 2004 Jan;130(1):52-6 - PubMed
    1. N Engl J Med. 2005 Mar 31;352(13):1317-23 - PubMed
    1. Leukemia. 2006 Jul;20(7):1254-60 - PubMed
    1. Mol Cell. 2002 Sep;10(3):457-68 - PubMed

MeSH terms

LinkOut - more resources

-